BGMS
Bio Green Med Solution, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$0.90
−1.96%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.9M | 747.0K | 43.0K | 420.0K | — |
| Cost of Revenue | 1.5M | 609.0K | — | — | 32.0K |
| Gross Profit | 360.0K | 138.0K | 43.0K | 420.0K | (32.0K) |
| Operating Expenses | |||||
| R&D Expense | (43.0K) | 848.0K | 6.7M | 19.2M | 20.3M |
| SG&A Expense | 3.1M | 7.7M | 5.4M | 6.7M | 7.4M |
| General & Admin Expense | 3.1M | 7.7M | 5.4M | 6.7M | 7.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 3.1M | 8.6M | 12.0M | 25.9M | 27.7M |
| Cost and Expenses | 4.6M | 9.2M | 12.0M | 25.9M | 27.7M |
| Operating Income (EBIT) | (2.7M) | (8.4M) | (12.0M) | (25.5M) | (27.7M) |
| Non-Operating | |||||
| Interest Income | 72.0K | 62.0K | 12.0K | 266.0K | 210.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 72.0K | 62.0K | 12.0K | 266.0K | 210.0K |
| Other Non-Op Income/Expense | 581.0K | 5.4M | 10.0K | (98.0K) | 1.7M |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (2.2M) | (3.0M) | (12.0M) | (25.6M) | (25.9M) |
| Income Tax Expense | 44.0K | 7.0K | (782.0K) | (3.0M) | (4.7M) |
| Bottom Line | |||||
| Net Income | (2.2M) | (3.0M) | (11.2M) | (22.6M) | (21.2M) |
| Earnings from Cont. Ops | (2.2M) | (3.0M) | (11.2M) | (22.6M) | (21.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (13.3M) | (14.1M) | (11.2M) | (22.8M) | (21.4M) |
| Per Share | |||||
| Basic EPS | ($3.64) | ($6.45) | ($501.60) | ($6,420.00) | ($6,840.00) |
| Diluted EPS | ($3.64) | ($6.45) | ($501.60) | ($6,420.00) | ($6,840.00) |
| Revenue Per Share | $0.33 | $0.34 | $1.16 | $118.48 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 5.6M | 2.2M | 36913 | 3545 | 3126 |
| Diluted Shares Outstanding | 5.6M | 2.2M | 36913 | 3545 | 3126 |
| Profitability Metrics | |||||
| EBITDA | (2.7M) | (8.4M) | (12.0M) | (25.4M) | (27.6M) |
| D&A | 7.5K | 5.0K | 6.0K | 31.0K | 32.0K |
| EBIT | (2.7M) | (8.4M) | (12.0M) | (25.5M) | (27.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026